Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Eterna Therapeutics Inc

NASDAQ ERNA
$1.26 0.03 2.87%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
9.60M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
10.15M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
53.36M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
332.76 %

Upcoming events Eterna Therapeutics Inc

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Eterna Therapeutics Inc

Stock analysis Eterna Therapeutics Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.21 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
2.33 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.26 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-0.01 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
774.69 -50.00

Price change Eterna Therapeutics Inc per year

0.16$ 2.63$
Min Max

Summary analysis Eterna Therapeutics Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Eterna Therapeutics Inc

Revenue and net income Eterna Therapeutics Inc

All parameters

About company Eterna Therapeutics Inc

Ernexa Therapeutics Inc., a preclinical-stage company focused on using cutting-edge gene-editing tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors. The company's lead product is ERNA-101, which is in preclinical stage for the treatment of ovarian cancer; and ERNA-102, that is in preclinical stage for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Address:
1035 Cambridge Street, Cambridge, MA, United States, 02141
Company name: Eterna Therapeutics Inc
Issuer ticker: ERNA
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 1992-10-19
Sector: Healthcare
Industry: Biotechnology
Site: https://eternatx.com